X0306 4/A 2016-10-24 2016-10-26 0 0001674416 CRISPR Therapeutics AG CRSP 0000816284 CELGENE CORP /DE/ 86 MORRIS AVENUE SUMMIT NJ 07901 0 0 1 0 Common Stock 2016-10-24 4 C 0 4034830 0.00 A 4034830 I See Explanation of Responses Common Stock 2016-10-24 4 P 0 800150 14.00 A 4834980 I See Explanation of Responses Series B Preferred Shares 0.00 2016-10-24 4 C 0 4034830 0.00 D 2016-10-24 Common Shares 4034830 0 I See Explanation of Responses These securities converted on a one-for-one basis into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering. These securities are held of record by Celgene Alpine Investment Co. III, LLC, an indirectly wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene may be deemed to have voting and investment power over these securities and as a result may be deemed to have beneficial ownership over such securities. Celgene disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that Celgene is a beneficial owner of such securities for the purpose of Section 16 and the Exchange Act, or for any other purpose. These securities were convertible at any time on a one-for-one basis into shares of the Issuer's Common Stock at the holder's election and automatically upon the closing of the Issuer's initial public offering. These securities do not have an expiration date. /s/ Peter N. Kellogg _______________________________________________________ Peter N. Kellogg, Executive Vice President and Chief Financial Officer 2016-10-27